Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Assets Average (2016 - 2025)

Ultragenyx Pharmaceutical has reported Assets Average over the past 10 years, most recently at $1.4 billion for Q4 2025.

  • Quarterly Assets Average fell 10.49% to $1.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Dec 2025, down 10.49% year-over-year, with the annual reading at $1.5 billion for FY2025, 1.37% up from the prior year.
  • Assets Average was $1.4 billion for Q4 2025 at Ultragenyx Pharmaceutical, up from $1.2 billion in the prior quarter.
  • Over five years, Assets Average peaked at $1.7 billion in Q1 2021 and troughed at $1.2 billion in Q3 2025.
  • The 5-year median for Assets Average is $1.5 billion (2022), against an average of $1.4 billion.
  • Year-over-year, Assets Average surged 41.74% in 2021 and then fell 20.91% in 2025.
  • A 5-year view of Assets Average shows it stood at $1.5 billion in 2021, then grew by 5.21% to $1.6 billion in 2022, then dropped by 13.74% to $1.4 billion in 2023, then increased by 11.44% to $1.5 billion in 2024, then dropped by 10.49% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for RARE's Assets Average are $1.4 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.3 billion (Q2 2025).